{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:57:49Z","timestamp":1740128269366,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,5,21]],"date-time":"2018-05-21T00:00:00Z","timestamp":1526860800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Neurovirol."],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s13365-018-0646-0","type":"journal-article","created":{"date-parts":[[2018,5,21]],"date-time":"2018-05-21T09:39:24Z","timestamp":1526895564000},"page":"570-576","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Anti-JC virus antibody sera positivity and index value among patients with multiple sclerosis may be correlated with age, sex, and area of residence"],"prefix":"10.1007","volume":"24","author":[{"given":"Sogol","family":"Koolaji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narges Sistany","family":"Allahabadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arash","family":"Ahmadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharareh","family":"Eskandarieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdorreza Naser","family":"Moghadasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir Reza","family":"Azimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3224-8807","authenticated-orcid":false,"given":"Mohammad Ali","family":"Sahraian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,21]]},"reference":[{"key":"646_CR1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jns.2016.03.050","volume":"365","author":"Y Aladro","year":"2016","unstructured":"Aladro Y, Terrero R, Cerezo M, Ginestal R, Ayuso L, Meca-Lallana V, Mill\u00e1n J, Borrego L, Martinez-Gin\u00e9s M, Rubio L, de Andr\u00e9s C, Miralles A, Guijarro C, Rodr\u00edguez-Garc\u00eda E, Garc\u00eda-Dominguez JM, Mu\u00f1oz-Fern\u00e1ndez C, L\u00f3pez de Silanes C, G\u00f3mez M, Thuissard I, Cerd\u00e1n M, Palm\u00ed I, D\u00edaz-Garz\u00f3n LF, Meca-Lallana J (2016) Anti-JC virus seroprevalence in a Spanish multiple sclerosis cohort. J Neurol Sci 365:16\u201321","journal-title":"J Neurol Sci"},{"key":"646_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jns.2015.11.044","volume":"360","author":"R Alroughani","year":"2016","unstructured":"Alroughani R, Akhtar S, Ahmed SF, Khoury SJ, Al-Hashel JY, Sahraian MA, Al Jumah M, Zeineddine M, Farhat S, Doumiati H, Yamout BI (2016) JC virus seroprevalence and seroconversion in multiple sclerosis cohort: a Middle-Eastern study. J Neurol Sci 360:61\u201365","journal-title":"J Neurol Sci"},{"issue":"Pt 7","key":"646_CR3","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1099\/vir.0.020115-0","volume":"91","author":"A Antonsson","year":"2010","unstructured":"Antonsson A, Green AC, Mallitt KA, O'Rourke PK, Pawlita M, Waterboer T, Neale RE (2010) Prevalence and stability of antibodies to the BK and JC polyomaviruses: a long-term longitudinal study of Australians. J Gen Virol 91(Pt 7):1849\u20131853","journal-title":"J Gen Virol"},{"key":"646_CR4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.msard.2017.01.006","volume":"12","author":"JR Berger","year":"2017","unstructured":"Berger JR (2017) Classifying PML risk with disease modifying therapies. Mult Scler Relat Disord 12:59\u201363","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"646_CR5","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1017\/cjn.2014.32","volume":"41","author":"V Bhan","year":"2014","unstructured":"Bhan V, Lapierre Y, Freedman MS, Duquette P, Selchen D, Migounov V, Walt L, Zhang A (2014) Anti-JC virus antibody prevalence in Canadian MS patients. Can J Neurol Sci 41(6):748\u2013752","journal-title":"Can J Neurol Sci"},{"issue":"20","key":"646_CR6","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","volume":"366","author":"G Bloomgren","year":"2012","unstructured":"Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C (2012) Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366(20):1870\u20131880","journal-title":"N Engl J Med"},{"issue":"5","key":"646_CR7","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/ana.22606","volume":"70","author":"C Bozic","year":"2011","unstructured":"Bozic C, Richman S, Plavina T, Natarajan A, Scanlon JV, Subramanyam M, Sandrock A, Bloomgren G (2011) Anti-John Cunningham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol 70(5):742\u2013750","journal-title":"Ann Neurol"},{"issue":"2","key":"646_CR8","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/ene.12304","volume":"21","author":"C Bozic","year":"2014","unstructured":"Bozic C, Subramanyam M, Richman S, Plavina T, Zhang A, Ticho B (2014) Anti-JC virus (JCV) antibody prevalence in the JCV epidemiology in MS (JEMS) trial. Eur J Neurol 21(2):299\u2013304","journal-title":"Eur J Neurol"},{"issue":"2","key":"646_CR9","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/eci.12721","volume":"47","author":"MI Dominguez-Mozo","year":"2017","unstructured":"Dominguez-Mozo MI, Rus M, Santiago JL, Izquierdo G, Casanova I, Galan V, Garcia-Martinez MA, Arias-Leal AM, Garcia-Montojo M, Perez-Perez S, Arroyo R, Alvarez-Lafuente R (2017) Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort. Eur J Clin Investig 47(2):158\u2013166","journal-title":"Eur J Clin Investig"},{"issue":"1","key":"646_CR10","first-page":"99","volume":"23","author":"F Elia","year":"2017","unstructured":"Elia F, Villani S, Ambrogi F, Signorini L, Dallari S, Binda S, Primache V, Pellegrinelli L, Ferrante P, Delbue S (2017) JC virus infection is acquired very early in life: evidence from a longitudinal serological study. J Neuro-Oncol 23(1):99\u2013105","journal-title":"J Neuro-Oncol"},{"issue":"3","key":"646_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0174005","volume":"12","author":"H Hegen","year":"2017","unstructured":"Hegen H, Auer M, Bsteh G, Di Pauli F, Plavina T, Walde J, Deisenhammer F, Berger T (2017) Stability and predictive value of anti-JCV antibody index in multiple sclerosis: a 6-year longitudinal study. PLoS One 12(3):e0174005","journal-title":"PLoS One"},{"issue":"5","key":"646_CR12","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/ane.12475","volume":"133","author":"M Kolasa","year":"2016","unstructured":"Kolasa M, Hagman S, Verkkoniemi-Ahola A, Airas L, Koivisto K, Elovaara I (2016) Anti-JC virus seroprevalence in a Finnish MS cohort. Acta Neurol Scand 133(5):391\u2013397","journal-title":"Acta Neurol Scand"},{"issue":"2","key":"646_CR13","first-page":"117","volume":"87","author":"C McGuigan","year":"2016","unstructured":"McGuigan C, Craner M, Guadagno J, Kapoor R, Mazibrada G, Molyneux P, Nicholas R, Palace J, Pearson OR, Rog D, Young CA (2016) Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry 87(2):117\u2013125","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"646_CR14","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/WCO.0000000000000202","volume":"28","author":"J Oh","year":"2015","unstructured":"Oh J, O'Connor PW (2015) Established disease-modifying treatments in relapsing-remitting multiple sclerosis. Curr Opin Neurol 28(3):220\u2013229","journal-title":"Curr Opin Neurol"},{"issue":"6","key":"646_CR15","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/ana.24286","volume":"76","author":"T Plavina","year":"2014","unstructured":"Plavina T, Subramanyam M, Bloomgren G, Richman S, Pace A, Lee S, Schlain B, Campagnolo D, Belachew S, Ticho B (2014) Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 76(6):802\u2013812","journal-title":"Ann Neurol"},{"issue":"9","key":"646_CR16","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354(9):899\u2013910","journal-title":"N Engl J Med"},{"issue":"8","key":"646_CR17","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1212\/01.WNL.0000158329.30470.D0","volume":"64","author":"GP Rice","year":"2005","unstructured":"Rice GP, Hartung HP, Calabresi PA (2005) Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 64(8):1336\u20131342","journal-title":"Neurology"},{"issue":"1","key":"646_CR18","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1212\/NXI.0000000000000195","volume":"3","author":"N Schwab","year":"2016","unstructured":"Schwab N, Schneider-Hohendorf T, Pignolet B, Breuer J, Gross CC, Gobel K, Brassat D, Wiendl H (2016) Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values. Neurol Neuroimmunol Neuroinflamm 3(1):e195","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"646_CR19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1177\/1352458511435105","volume":"18","author":"PS Sorensen","year":"2012","unstructured":"Sorensen PS, Bertolotto A, Edan G, Giovannoni G, Gold R, Havrdova E, Kappos L, Kieseier BC, Montalban X, Olsson T (2012) Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 18(2):143\u2013152","journal-title":"Mult Scler"},{"key":"646_CR20","doi-asserted-by":"publisher","unstructured":"Tramacere I, Del Giovane C, Salanti G, D'Amico R, Filippini G (2015) Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev 9:Cd011381. \n                    https:\/\/doi.org\/10.1002\/14651858.CD011381.pub2","DOI":"10.1002\/14651858.CD011381.pub2"},{"issue":"Suppl 3","key":"646_CR21","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1093\/infdis\/jiu159","volume":"209","author":"J Lunzen van","year":"2014","unstructured":"van Lunzen J, Altfeld M (2014) Sex differences in infectious diseases-common but neglected. J Infect Dis 209(Suppl 3):S79\u2013S80","journal-title":"J Infect Dis"},{"issue":"6","key":"646_CR22","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1111\/ene.12988","volume":"23","author":"A Vennegoor","year":"2016","unstructured":"Vennegoor A, van Rossum JA, Leurs C, Wattjes MP, Rispens T, Murk JL, Uitdehaag BM, Killestein J (2016) High cumulative JC virus seroconversion rate during long-term use of natalizumab. Eur J Neurol 23(6):1079\u20131085","journal-title":"Eur J Neurol"}],"container-title":["Journal of NeuroVirology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13365-018-0646-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-018-0646-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-018-0646-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T15:08:25Z","timestamp":1558451305000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13365-018-0646-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,21]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["646"],"URL":"https:\/\/doi.org\/10.1007\/s13365-018-0646-0","relation":{},"ISSN":["1355-0284","1538-2443"],"issn-type":[{"type":"print","value":"1355-0284"},{"type":"electronic","value":"1538-2443"}],"subject":[],"published":{"date-parts":[[2018,5,21]]},"assertion":[{"value":"23 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}